This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating MT
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Corporation Announces Board Changes CI
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating MT
Deutsche Bank on Bausch + Lomb's Q4 MT
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
RBC Raises Bausch + Lomb Target to US$20, Reiterates Outperform, After Q4 MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept MT
Sector Update: Health Care Stocks Mixed in Late Afternoon MT
Needham Reviews Bausch + Lomb's Q4 MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Sector Update: Health Care MT
Toronto Stocks Slide; Gildan Activewear Rises on 4Q Earnings Beat DJ
Bausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed Views MT
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Ahead of Fed Meeting Minutes MT
Bausch + Lomb Q4 Revenue of US$1.173 Billion; GAAP Net Loss Attributable to Co of $54 Million; Provides 2024 Guidance MT
Transcript : Bausch + Lomb Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Bausch + Lomb's Q4 Adjusted Earnings, Revenue Increase; Issues 2024 Revenue Guidance; Shares Rise Pre-Bell MT
Bausch + Lomb Brief: Q4 Revenue of US$1.173 Billion; GAAP Net Loss Attributable to Co of $54 Million; Provides 2024 Guidance MT
Bausch + Lomb Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Chart Bausch + Lomb Corporation
More charts
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
14.31 USD
Average target price
19.92 USD
Spread / Average Target
+39.20%
Consensus
  1. Stock Market
  2. Equities
  3. BLCO Stock
  4. News Bausch + Lomb Corporation
  5. Bausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed Views